Introduction

At AstraZeneca we are dedicated to redefining the future of healthcare by unlocking the power of what science can do for people, society and the planet. Working here means being bold, thinking big and working together to use the potential of science to address the unmet needs of patients around the world.

To deliver our medicines to patients we need to develop evidence for health technology assessment (HTA) bodies and payers around the world. This requires expertise in HTA science where we can translate data into evidence to support decision‑making across the lifecycle of our medicines. In Europe, the start of the Joint Clinical Assessment (JCA) will require innovative solutions in demonstrating our comparative effectiveness through direct and indirect analyses, and consideration of how we pull through such evidence into economic value at the national level.

With our expanding oncology portfolio and increasing use of HTA around the globe, we ar...